Second episodes of Haemophilus influenzae type b disease following rifampin prophylaxis of the index patients.
Patients treated for Haemophilus influenzae type b disease frequently remain nasopharyngeal carriers of that organism and fail to develop protective concentrations of serum antibody. It has been suggested that rifampin prophylaxis of the index patient may prevent recurrence of disease by eliminating type b Haemophilus carriage. We report nine children who developed second episodes of disease 1 week or more after receiving rifampin prophylaxis. The median interval between the last dose of rifampin and admission to the hospital for the second episode was 70 days (range, 9 to 138). Analysis of biotypes and outer membrane protein polyacrylamide gel electrophoresis patterns of paired isolates from eight cases revealed that the second episodes in two of the children were caused by acquisition of new type b Haemophilus strains, whereas the second episodes in the remaining six children were caused by isolates which were indistinguishable from the respective isolates from the first episodes. Rifampin prophylaxis of the index patient may prevent some episodes of recurrent disease. However, in some patients who have received prophylaxis, second episodes can occur, probably as a result of reacquisition of the organism from contacts who did not receive rifampin or from acquisition of new type b strains.
D001425:Bacterial Outer Membrane Proteins / Q000032:analysis; D002353:Carrier State / Q000188:drug therapy*; D004591:Electrophoresis, Polyacrylamide Gel; D005260:Female; D006192:Haemophilus Infections / Q000188:drug therapy* / Q000382:microbiology; D006193:Haemophilus influenzae / Q000145:classification; D006801:Humans; D007223:Infant; D008297:Male; D012008:Recurrence; D012293:Rifampin / Q000627:therapeutic use*
D001425:Bacterial Outer Membrane Proteins; D012293:Rifampin